Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inari Medical reports robust Q4 earnings and eyes international expansion

Inari Medical's Q4 2022 earnings call highlighted strong revenue growth, operational challenges, and strategic opportunities for market expansion and product innovation.
The company's focus on patient outcomes, superior product performance, and international growth positions it for continued success in 2023 and beyond.
Efforts to optimize gross margins, manage operating expenses, and drive market adoption present key areas for Inari's future financial performance and profitability.
With a clear revenue guidance for 2023 and a commitment to sustained operating profitability, Inari Medical demonstrates a strategic roadmap for sustainable growth.

Inari Medical reports robust Q1 earnings, eyes sustained profitability

Inari Medical's Q1 earnings call highlighted strong financial performance, growth strategies, and product innovations. Challenges include competitive dynamics and assessing seasonality trends. The company is well-positioned for sustained growth and market expansion.

Inari Medical reports record revenue and eyes Asian market expansion

Inari Medical's Q2 2023 performance reflects robust financial growth, international expansion, and a strategic focus on addressing unmet needs in the CVD market.
With a strong product portfolio, sustained profitability, and market development initiatives, Inari Medical is well-equipped to capitalize on growth opportunities and drive innovation.
Challenges in market entry, product redesign timelines, and regulatory approvals are being navigated as the company aims for sustained growth and market leadership in the medical device sector.

Inari Medical reports robust Q3 earnings, acquires LimFlow for growth

Inari Medical's Q3 performance reflects strong financial growth, operational improvements, and strategic acquisitions driving future prospects.
While challenges like declining margins and delayed profit targets exist, opportunities in new markets, product pricing, and synergies offer avenues for sustained growth.
The LimFlow acquisition positions Inari well in the CLTI market, with a focus on revenue growth, operational efficiency, and market expansion.
Overall, Inari's confidence in its core business and strategic moves like the LimFlow acquisition signal a positive trajectory and growth outlook.

Inari Medical reports record revenue, eyes sustained profitability amid challenges

Inari Medical's Q4 2023 performance showcased strong revenue growth, operational progress, and a strategic focus on market leadership and patient care.
While facing challenges such as regulatory scrutiny and increased operating expenses, the company remains optimistic about revenue growth and sustained profitability.
Opportunities lie in diversified revenue streams, international expansion, and product portfolio enhancements, positioning Inari for continued growth and market leadership.
Overall, Inari Medical's strategic initiatives and financial performance indicate a resilient and growth-oriented trajectory in the medical device industry.

Inari Medical reports record Q1 revenue, raises full-year guidance

Inari Medical's Q1 performance reflects robust revenue growth, strategic investments, and international expansion, positioning the company for sustained profitability and market leadership.
While facing challenges in competition and market dynamics, Inari's strengths in innovation, global performance, and product development offer avenues for growth and differentiation.
The company's focus on operational efficiency, strategic investments, and product enhancements align with opportunities in expanding toolkits, new therapies, and market presence.

Inari Medical reports record revenue, eyes sustained profitability and global expansion

Inari Medical's Q2 2024 performance reflects strong revenue growth but with operating losses, signaling a need for cost management strategies.
The company's strategic strengths lie in sustained profitability projections, successful business integrations, and expansion into key international markets.
Challenges include leadership transition risks, operational hurdles in new markets, and the need to meet high market expectations with upcoming data releases.
Opportunities for Inari include optimizing costs, leveraging growth in China and Japan, capitalizing on new product adoption, and driving further market expansion.

Inari Medical reports record revenue and eyes global expansion

Inari Medical's Q3 performance reflects robust revenue growth and strategic focus on expanding therapies globally.
The company's strengths lie in revised revenue guidance, upcoming profitability, and promising study outcomes.
Challenges include managing expenses, reducing losses, and sustaining high margins amidst market competition.
Opportunities abound in driving growth, capitalizing on new therapies, and expanding market presence internationally.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

Inari Medical Inc. increased that number of shares it was selling in its initial public offering, which priced late Thursday above the expected range.

Inari Medical increases shares it sold in IPO, which priced above the expected range

News for Inari Medical Stock (NARI)